<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172676</url>
  </required_header>
  <id_info>
    <org_study_id>ITPHP</org_study_id>
    <nct_id>NCT03172676</nct_id>
  </id_info>
  <brief_title>Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura</brief_title>
  <official_title>Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombocytopenia refers to a reduction in platelet count to (&lt;150 × 109/L). Immune
      thrombocytopenic purpura is an acquired autoimmune disorder defined by isolated
      thrombocytopenia and the exclusion of other causes of thrombocytopenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori was recently demonstrated as an etiological factor in immune
      thrombocytopenic purpura in some prospective studies, with reports of platelet numbers
      increasing in these patients after Helicobacter pylori eradication treatment.However, other
      studies have shown a negative result after eradication treatment of Helicobacter pylori
      infection in patients with chronic immune thrombocytopenic purpura, leading to controversy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effects of Helicobacter pylori infection eradication on platelet counts of chronic immune thrombocytopenic patients</measure>
    <time_frame>6 months</time_frame>
    <description>platelet counts will be measured at the start of the study ,before the starting of the interventions, and after 6 months. platelet response will be classified as: 1-complete response: platelet count&gt; 150 × 109/L , 2-partial response: platelet count : 50-150 × 109/L , no response: platelet count &lt; 50 × 109/L.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Helicobacter pylori negative patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>chronic immune thrombocytopenic purpura patients who will be diagnosed negative for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Helicobacter pylori positive patients with intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will receive treatment of Helicobacter pylori: Amoxicillin for 14 days, Clarithromycin for 14 days and Proton pump inhibitor for one month).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Helicobacter pylori positive patients without intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will not receive treatment of Helicobacter pylori during the study,these patient group will receive treatment of Helicobacter pylori after the end of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.</intervention_name>
    <description>chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.</description>
    <arm_group_label>Helicobacter pylori positive patients with intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.</intervention_name>
    <description>chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.</description>
    <arm_group_label>Helicobacter pylori positive patients with intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month</intervention_name>
    <description>chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.</description>
    <arm_group_label>Helicobacter pylori positive patients with intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. chronic immune thrombocytopenic purpura patients who still have thrombocytopenia &gt; 12
             months

          2. age &lt;18 years .

          3. diagnosis of immune thrombocytopenic purpura according to American Society of
             Hematology criteria based on an initial platelet count &lt;100×103/μL .

          4. Patients diagnosed as steroid and immunoglobulin resistant chronic immune
             thrombocytopenic purpura .

        exclusion criteria:

          1. Patients with acute immune thrombocytopenic purpura . .

          2. age &gt;18 years.

          3. thrombocytopenia was related to autoimmune disorders, drugs, a family history
             consistent with inherited thrombocytopenia, human immunodeficiency virus infection,
             hepatitis.

          4. previous history of Helicobacter pylori eradication; and history of medication with
             proton pump inhibitors, H2- receptor antagonists, or antibiotics in the previous 4
             weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fahim Mohamed, MD</last_name>
    <phone>00201002500073</phone>
    <email>fahim.osman@med.au.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mervat Amin, MD</last_name>
    <phone>00201142606221</phone>
    <email>mamuosif2002@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Loffredo G, Marzano MG, Migliorati R, Miele E, Menna F, Poggi V, Staiano A. The relationship between immune thrombocytopenic purpura and Helicobacter pylori infection in children: where is the truth? Eur J Pediatr. 2007 Oct;166(10):1067-8. Epub 2006 Nov 29.</citation>
    <PMID>17136353</PMID>
  </reference>
  <reference>
    <citation>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563. Epub 2017 Jan 10.</citation>
    <PMID>28071659</PMID>
  </reference>
  <reference>
    <citation>Treepongkaruna S, Sirachainan N, Kanjanapongkul S, Winaichatsak A, Sirithorn S, Sumritsopak R, Chuansumrit A. Absence of platelet recovery following Helicobacter pylori eradication in childhood chronic idiopathic thrombocytopenic purpura: a multi-center randomized controlled trial. Pediatr Blood Cancer. 2009 Jul;53(1):72-7. doi: 10.1002/pbc.21991.</citation>
    <PMID>19301380</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mary Makram Kamel</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

